Navigation Links
VIVUS to Present at the Canaccord Adams 29th Annual Global Growth Conference
Date:8/4/2009

MOUNTAIN VIEW, Calif., Aug. 4 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that Timothy Morris, chief financial officer, will present an overview of the company at the Canaccord Adams 29th Annual Global Growth Conference in Boston.

The VIVUS presentation will take place at the Intercontinental Hotel on Thursday, August 13, 2009 at 8:30 a.m. ET. A live webcast and 30-day archive of the presentation will be available at http://www.wsw.com/webcast/canaccord/vvus or http://www.vivus.com.

About VIVUS

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead investigational product in clinical development, Qnexa(TM), is expected to complete Phase 3 clinical trials for the treatment of obesity in 2009. Qnexa is also in Phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in Phase 3 development with avanafil, its PDE5 inhibitor drug candidate, and in Phase 2 development of Luramist(TM), its drug candidate for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.

    CONTACT:             VIVUS, Inc.
                         Timothy E. Morris
                         Chief Financial Officer
                         +1-650-934-5200

    INVESTOR RELATIONS:  The Trout Group
                         Brian Korb
                         +1-646-378-2923

    MEDIA RELATIONS:     Pure Communications, Inc.
                         Sheryl Seapy
                         +1-949-608-0841


'/>"/>
SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. VIVUS to Present at the Needham and Company Life Sciences Conference
2. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
3. VIVUS Reports First Quarter 2009 Financial Results and Highlights
4. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
5. Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer
6. Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City
7. Stemline Therapeutics CEO to Present at IBCs New Frontiers in Cancer Drug Development Conference
8. PDL BioPharma to Present at BMO Capital Markets Healthcare Conference on August 5, 2009
9. Patent Awarded for a New X-ray Imaging Technology with Capability Unrealized with Present Day Radiological Modalities
10. NovaBay(R) Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference
11. Histogen Hair Regrowth Clinical Trial Presented at ISHRS Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... ... May 22, 2017 , ... Stratevi, a boutique firm that partners with healthcare ... has opened an office in downtown Boston at 745 Atlantic Ave. , “We ... to generate evidence on the value they provide, not just to patients, but also ...
(Date:5/21/2017)... ... May 19, 2017 , ... Ovation Fertility scientists’ work is ... of Bioanalysts (AAB) and the College of Reproductive Biology (CRB) today and Saturday ... to excellence in clinical laboratory services and regulations. , “We are pleased ...
(Date:5/19/2017)... ... May 19, 2017 , ... The University City ... with technologies ripe for commercialization, and who are affiliated with the 21 partner ... submit proposals. QED, now in its tenth round, is the first multi-institutional proof-of-concept ...
(Date:5/18/2017)... ... 16, 2017 , ... Clinical Supplies Management (“CSM”), a Great Point Partners II ... grow. CSM has doubled in size over the past six months with the ... , Roger Gasper joins CSM as Chief Financial Officer. Roger has over 25 ...
Breaking Biology Technology:
(Date:4/24/2017)... 2017 Janice Kephart , former ... Strategy Partners, LLP (IdSP) , today issues the ... Trump,s March 6, 2017 Executive Order: Protecting ... can be instilled with greater confidence, enabling the ... refugee applications are suspended by until at least ...
(Date:4/13/2017)... , April 13, 2017 According to a new ... Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, ... IAM Market is expected to grow from USD 14.30 Billion in 2017 ... (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), Biometrics, Card-Based ... & Logistics, Government & Public Sector, Utilities / Energy ... Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality & ... for a definitive report on the $27.9bn Access Control ... ...
Breaking Biology News(10 mins):